Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Destabilization of Microtubules01:45

Destabilization of Microtubules

3.6K
The destabilization of microtubules can occur during different stages of the microtubule lifecycle, such as nucleation or elongation. It can take place at either end of the microtubule or in the microtubule lattices as a whole. The lifespan of individual microtubules within a cell varies according to the cell type and stage of the cell cycle. During interphase, the lifespan of the microtubule is about 30 minutes, while during cell division, it is about 15 minutes. In axonal microtubules of...
3.6K
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

3.8K
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
3.8K
Tumor Immunotherapy01:27

Tumor Immunotherapy

2.0K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.0K
Introduction to Nuclear Reprogramming01:14

Introduction to Nuclear Reprogramming

2.3K
Nuclear reprogramming is the process of switching gene expression of one cell type to that of another cell type, usually from a differentiated cell state to an undifferentiated cell state. Differentiation occurs during processes such as development and morphogenesis, tissue regeneration, and malignancy. Cells can also be artificially induced to reprogram their gene expression by techniques such as nuclear transfer, induced pluripotency, and cell fusion. Such techniques have many applications in...
2.3K
Methods of Nuclear Reprogramming01:24

Methods of Nuclear Reprogramming

2.1K
Nuclear reprogramming is a process of transforming one cell type into an unrelated cell type by epigenetic changes that alter the cell’s original gene expression pattern. Such epigenetic changes force cells to express a different set of genes, which play a significant role in inducing transformation into other cell types. Nuclear reprogramming offers applications in reproductive cloning for livestock propagation and regenerative medicine — developing patient-specific cells for...
2.1K
Somatic to iPS Cell Reprogramming01:29

Somatic to iPS Cell Reprogramming

2.7K
Reprogramming alters the gene expression in somatic cells, transforming them into induced pluripotent stem (iPS) cells over several generations. Scientists can reprogram cells by introducing genes for four transcription factors—Oct4, Sox2, Klf4, and c-Myc (OSKM) by viral or non-viral methods. These factors are also known as Yamanaka factors after Shinya Yamanaka, who first generated iPS cells using mouse skin cells. Yamanaka was awarded the Nobel Prize in Physiology or Medicine in 2012...
2.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

BTK inhibition enhances immunovirotherapy in glioblastoma via tertiary lymphoid structure modulation.

bioRxiv : the preprint server for biology·2026
Same author

Brain CD73 modulates interferon signaling to regulate glioblastoma invasion.

Neuro-oncology advances·2025
Same author

β-blocker suppresses both tumoral sympathetic neurons and perivascular macrophages during oncolytic herpes virotherapy.

Journal for immunotherapy of cancer·2025
Same author

UFL1 promotes survival and function of virtual memory CD8 T cells.

Journal of immunology (Baltimore, Md. : 1950)·2025
Same author

Lymph node macrophages drive immune tolerance and resistance to cancer therapy by induction of the immune-regulatory cytokine IL-33.

Cancer cell·2025
Same author

Blocking Feedback Immunosuppression of Antigen Presentation in Brain Tumor During Oncolytic Virotherapy with oHSV-mshPKR.

Molecular cancer therapeutics·2024

Related Experiment Video

Updated: Feb 5, 2026

Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets
07:08

Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets

Published on: February 2, 2024

1.5K

Treg Destabilization and Reprogramming: Implications for Cancer Immunotherapy.

David H Munn1,2, Madhav D Sharma3,2, Theodore S Johnson3,2

  • 1Georgia Cancer Center, Augusta University, Augusta, Georgia. dmunn@augusta.edu.

Cancer Research
|September 6, 2018
PubMed
Summary

Regulatory T cells (Tregs) can lose suppressor activity and become proinflammatory when exposed to certain signals. However, tumors stabilize Tregs, inhibiting antitumor immunity. Targeting Treg stabilization pathways may enhance cancer therapies.

More Related Videos

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells
10:04

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells

Published on: August 1, 2025

1.6K
Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
06:51

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

16.0K

Related Experiment Videos

Last Updated: Feb 5, 2026

Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets
07:08

Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets

Published on: February 2, 2024

1.5K
Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells
10:04

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells

Published on: August 1, 2025

1.6K
Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
06:51

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

16.0K

Area of Science:

  • Immunology
  • Cancer Biology
  • Cellular Biology

Background:

  • Regulatory T cells (Tregs) are crucial for the immunosuppressive tumor microenvironment.
  • Targeting Tregs for cancer therapy remains challenging due to their complex biology.
  • Tregs exhibit functional instability under specific inflammatory conditions, potentially losing suppressor activity.

Purpose of the Study:

  • To review the emerging understanding of Treg functional instability and stabilization in the tumor microenvironment.
  • To propose a hypothesis regarding Treg phenotypic modulation as a physiologic response rather than lineage infidelity.
  • To identify potential therapeutic strategies by targeting Treg stabilization pathways.

Main Methods:

  • Literature review of Treg biology, focusing on functional instability and stabilization mechanisms.
  • Analysis of inflammatory signals (IL-6, IFNγ) and stabilizing factors (IDO, PTEN) in the context of tumor-associated Tregs.
  • Hypothesis generation based on current evidence regarding Treg plasticity and tumor immune evasion.

Main Results:

  • Certain inflammatory signals can induce rapid loss of Treg suppressor function and promote a proinflammatory phenotype.
  • Tumor-associated Tregs are stabilized by factors like indoleamine 2,3-dioxygenase (IDO) and PTEN, maintaining immunosuppression.
  • This Treg stabilization inhibits the cross-presentation of tumor antigens, hindering antitumor immune responses.

Conclusions:

  • Inflammation-induced Treg destabilization is a natural process, but tumors actively counteract it.
  • Targeting Treg stabilizing pathways could sensitize tumor-associated Tregs to destabilization during immunotherapy or cytotoxic treatments.
  • Understanding Treg stabilization/destabilization pathways offers novel molecular targets for enhancing antitumor immunity.